Cargando…

Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer

BACKGROUND: Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Although marker genes associated with CRC have been identified previously, only a few have fulfilled the therapeutic demand. Therefore, based on differentially expressed genes (DEGs), this study aimed to est...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Di, Liufu, Junye, Yang, Qiyuan, Dai, Shengqun, Wang, Jiaqi, Xie, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628086/
https://www.ncbi.nlm.nih.gov/pubmed/36319976
http://dx.doi.org/10.1186/s13062-022-00342-w
_version_ 1784823121073668096
author Wang, Di
Liufu, Junye
Yang, Qiyuan
Dai, Shengqun
Wang, Jiaqi
Xie, Biao
author_facet Wang, Di
Liufu, Junye
Yang, Qiyuan
Dai, Shengqun
Wang, Jiaqi
Xie, Biao
author_sort Wang, Di
collection PubMed
description BACKGROUND: Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Although marker genes associated with CRC have been identified previously, only a few have fulfilled the therapeutic demand. Therefore, based on differentially expressed genes (DEGs), this study aimed to establish a promising and valuable signature model to diagnose CRC and predict patient’s prognosis. METHODS: The key genes were screened from DEGs to establish a multiscale embedded gene co-expression network, protein-protein interaction network, and survival analysis. A support vector machine (SVM) diagnostic model was constructed by a supervised classification algorithm. Univariate Cox analysis was performed to construct two prognostic signatures for overall survival and disease-free survival by Kaplan–Meier analysis, respectively. Independent clinical prognostic indicators were identified, followed by univariable and multivariable Cox analysis. GSEA was used to evaluate the gene enrichment analysis and CIBERSORT was used to estimate the immune cell infiltration. Finally, key genes were validated by qPCR and IHC. RESULTS: In this study, four key genes (DKC1, FLNA, CSE1L and NSUN5) were screened. The SVM diagnostic model, consisting of 4-gene signature, showed a good performance for the diagnostic (AUC = 0.9956). Meanwhile, the four-gene signature was also used to construct a risk score prognostic model for disease-free survival (DFS) and overall survival (OS), and the results indicated that the prognostic model performed best in predicting the DFS and OS of CRC patients. The risk score was validated as an independent prognostic factor to exhibit the accurate survival prediction for OS according to the independent prognostic value. Furthermore, immune cell infiltration analysis demonstrated that the high-risk group had a higher proportion of macrophages M0, and T cells CD4 memory resting was significantly higher in the low-risk group than in the high-risk group. In addition, functional analysis indicated that WNT and other four cancer-related signaling pathways were the most significantly enriched pathways in the high-risk group. Finally, qRT-PCR and IHC results demonstrated that the high expression of DKC1, CSE1L and NSUN5, and the low expression of FLNA were risk factors of CRC patients with a poor prognosis. CONCLUSION: In this study, diagnosis and prognosis models were constructed based on the screened genes of DKC1, FLNA, CSE1L and NSUN5. The four-gene signature exhibited an excellent ability in CRC diagnosis and prognostic prediction. Our study supported and highlighted that the four-gene signature is conducive to better prognostic risk stratification and potential therapeutic targets for CRC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13062-022-00342-w.
format Online
Article
Text
id pubmed-9628086
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96280862022-11-03 Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer Wang, Di Liufu, Junye Yang, Qiyuan Dai, Shengqun Wang, Jiaqi Xie, Biao Biol Direct Research BACKGROUND: Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Although marker genes associated with CRC have been identified previously, only a few have fulfilled the therapeutic demand. Therefore, based on differentially expressed genes (DEGs), this study aimed to establish a promising and valuable signature model to diagnose CRC and predict patient’s prognosis. METHODS: The key genes were screened from DEGs to establish a multiscale embedded gene co-expression network, protein-protein interaction network, and survival analysis. A support vector machine (SVM) diagnostic model was constructed by a supervised classification algorithm. Univariate Cox analysis was performed to construct two prognostic signatures for overall survival and disease-free survival by Kaplan–Meier analysis, respectively. Independent clinical prognostic indicators were identified, followed by univariable and multivariable Cox analysis. GSEA was used to evaluate the gene enrichment analysis and CIBERSORT was used to estimate the immune cell infiltration. Finally, key genes were validated by qPCR and IHC. RESULTS: In this study, four key genes (DKC1, FLNA, CSE1L and NSUN5) were screened. The SVM diagnostic model, consisting of 4-gene signature, showed a good performance for the diagnostic (AUC = 0.9956). Meanwhile, the four-gene signature was also used to construct a risk score prognostic model for disease-free survival (DFS) and overall survival (OS), and the results indicated that the prognostic model performed best in predicting the DFS and OS of CRC patients. The risk score was validated as an independent prognostic factor to exhibit the accurate survival prediction for OS according to the independent prognostic value. Furthermore, immune cell infiltration analysis demonstrated that the high-risk group had a higher proportion of macrophages M0, and T cells CD4 memory resting was significantly higher in the low-risk group than in the high-risk group. In addition, functional analysis indicated that WNT and other four cancer-related signaling pathways were the most significantly enriched pathways in the high-risk group. Finally, qRT-PCR and IHC results demonstrated that the high expression of DKC1, CSE1L and NSUN5, and the low expression of FLNA were risk factors of CRC patients with a poor prognosis. CONCLUSION: In this study, diagnosis and prognosis models were constructed based on the screened genes of DKC1, FLNA, CSE1L and NSUN5. The four-gene signature exhibited an excellent ability in CRC diagnosis and prognostic prediction. Our study supported and highlighted that the four-gene signature is conducive to better prognostic risk stratification and potential therapeutic targets for CRC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13062-022-00342-w. BioMed Central 2022-11-02 /pmc/articles/PMC9628086/ /pubmed/36319976 http://dx.doi.org/10.1186/s13062-022-00342-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Di
Liufu, Junye
Yang, Qiyuan
Dai, Shengqun
Wang, Jiaqi
Xie, Biao
Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
title Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
title_full Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
title_fullStr Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
title_full_unstemmed Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
title_short Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
title_sort identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628086/
https://www.ncbi.nlm.nih.gov/pubmed/36319976
http://dx.doi.org/10.1186/s13062-022-00342-w
work_keys_str_mv AT wangdi identificationandvalidationofanovelsignatureasadiagnosticandprognosticbiomarkerincolorectalcancer
AT liufujunye identificationandvalidationofanovelsignatureasadiagnosticandprognosticbiomarkerincolorectalcancer
AT yangqiyuan identificationandvalidationofanovelsignatureasadiagnosticandprognosticbiomarkerincolorectalcancer
AT daishengqun identificationandvalidationofanovelsignatureasadiagnosticandprognosticbiomarkerincolorectalcancer
AT wangjiaqi identificationandvalidationofanovelsignatureasadiagnosticandprognosticbiomarkerincolorectalcancer
AT xiebiao identificationandvalidationofanovelsignatureasadiagnosticandprognosticbiomarkerincolorectalcancer